Emkay Global Financial's report on HCL Tech
HCLT delivered broadly in line operating performance in Q4. Revenue grew 0.5% QoQ to USD2.99bn (1.1% CC) on the back of continued traction in Services (5% CC). Products & Platforms declined 24% CC due to seasonality. EBITM declined by 110bps to 17.9%. It signed 6 large services and 4 product deals across technology & services, life sciences & healthcare and public services verticals for a total new deal TCV of USD2.3bn (6% QoQ). Broad-based demand, robust deal intake and pipeline augur well for revenue acceleration. HCLT has guided for revenue growth of 12-14% CC in FY23 on the back of continued traction in the services business, healthy deal intake and deal pipeline (close to all time high). It has guided for 18-20% EBITM guidance for FY23, considering supply-side challenges and planned investments in Mode 2 capabilities and markets.
Outlook
We cut FY23/FY24 EPS estimates by 3%/2.7%, factoring in Q4 performance and FY23 guidance. Revenue growth momentum is encouraging; however, pressure on Services margin led to earnings cut. We maintain Buy with a TP of Rs1,400 at 22x Mar'24E EPS considering attractive valuations, steady cash generation and ~4% dividend yield.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!